Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Hyrimoz is a prescription tumor necrosis factor blocker containing adalimumab-adaz. FDA lists it as an interchangeable biosimilar to Humira. Current U.S. labeling includes rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and noninfectious uveitis.
read more about hyrimoz ...Adalimumab-adaz binds specifically to tumor necrosis factor alpha and blocks its interaction with p55 and p75 cell-surface TNF receptors. TNF-alpha participates in inflammatory and immune signaling and is elevated in several diseases treated with adalimumab products.
Adult indications include rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis. Pediatric labeling includes juvenile idiopathic arthritis and uveitis from age 2, Crohn disease from age 6, and hidradenitis suppurativa from age 12.
Dosing depends on the condition, age, and body weight. Adults with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis receive 40 mg subcutaneously every other week. Crohn disease, plaque psoriasis, hidradenitis suppurativa, and uveitis use indication-specific loading and maintenance schedules.
Hyrimoz carries boxed warnings for serious infections and malignancies. Risks include tuberculosis, bacterial sepsis, invasive fungal infections, lymphoma, and other cancers. Other serious concerns include hepatitis B reactivation, neurologic reactions, blood-cell abnormalities, worsening heart failure, hypersensitivity, and autoimmune reactions.
Yes. FDA lists Hyrimoz as an interchangeable biosimilar to Humira.
The recommended dose is 40 mg by subcutaneous injection every other week.
Yes. Current labeling calls for latent tuberculosis testing before treatment and during therapy.
Yes. The boxed warnings concern serious infections and malignancies.
Adalimumab Injection. MedlinePlus. https://medlineplus.gov/druginfo/meds/a603010.html. Date Accessed October 1, 2026.
Adalimumab. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Adalimumab. Date Accessed October 1, 2026.
Biosimilar Product Information. U.S. Food and Drug Administration. https://www.fda.gov/drugs/biosimilars/biosimilar-product-information. Date Accessed October 1, 2026.
DailyMed - HYRIMOZ (adalimumab-adaz) injection, solution. https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3e303a4a-980b-4f2a-9d03-786928758637. Date Accessed October 1, 2026.
Purple Book Search - Hyrimoz. U.S. Food and Drug Administration. https://purplebooksearch.fda.gov/index.cfm?blaNo=761071&event=productdetails. Date Accessed October 1, 2026.